medigraphic.com
Academia Mexicana de Neurología, A.C.

2007, Número 3

<< Anterior Siguiente >>

Rev Mex Neuroci 2007; 8 (3)


Manifestaciones neurológicas en infección por HTLV-I

Alarcón GT, Hidalgo SC, Aguirre NR, Diaz CE, Santibáñez VR, Navas PC

Idioma: Español
Referencias bibliográficas: 65
Paginas: 234-240
Archivo PDF: 113.21 Kb.


RESUMEN

Introducción: El HAM/TSP es una mieloneuropatía crónica, endémica en varios países del orbe relacionada con el retrovirus HTLV-I, para la cual existen criterios clínicos y diagnósticos establecidos. Métodos: Se revisa su etiología e inmunología y con base en 45 casos diagnosticados y seguidos en nuestro Servicio desde 1992 a la fecha, se valoran los criterios de inclusión, la escala de valoración (Osame’s motor disability scale) y los exámenes en sangre, LCR, radiológicos (especialmente RM) y neurofisiológicos que coadyuvan al diagnóstico, lo que en nuestra serie es similar a lo encontrado por otros autores. Resultados: Se enumera las posibilidades de tratamiento y se enfatiza la necesidad de estudios neuroepidemiológicos que determinen una mejor prevención y control de la enfermedad. Conclusiones: Comprobada la existencia del HAM/TSP y su relación con el HTLV-1, amerita realizar estudios epidemiológicos, sobre todo en áreas endémicas y poblacionales donde ocasionalmente hay que emplear un diagnóstico diferencial que puede tornarse difícil, ya que mielopatías de otras etiologías (particularmente la esclerosis múltiple en su forma primaria progresiva) pueden confundirse con el HAM/TSP.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Poiez BJ, Ruscetti FW, et al. Detection and isolation of type C Retrovirus particle from fresh and cultured lymphocytes of a patients with cutaneus T cell lymphoma. Proc Nat Acad Sci USA 1980; 77: 7415.

  2. Osame M,Usuku K, Izumu S, Aminati H. HTLV-1 associated myelophaty, a new clinical entity. Lancet 1986; 1: 1031.

  3. Cartier L, Mora C, Araya F, et al. HTLV-1 positive spastic paraparesis in a temperater zone. Lancet 1989; 1: 556-7.

  4. Zaninoviv W, Biojo R, Barreto PL. Paraparesia espástica del Pacífico. Colombia Med 1981; 12: 111-17.

  5. Gessain A, Louis A, Gallo RC. Human T cell Leukemialymphoma virus type I (HTLV-1) expression in fresh peripherical blood with TSP/HTLV-1 associated myelophaty. J Virol 1991: 64: 1628-33.

  6. Montgomery RD, Cruickshank EK, Robertson WB. Clinical and pathological observations on Jamaican neuropathy: a report on 206 cases. Brain 1964; 87: 425.

  7. Dueñas-Barajas E, Bernal JE, Vaugth DR, et al. Human Retroviruses in Ameridians in Colombia. Prevalence oh human T lynphotropic virus type II among the tunebo Indians. Am J Trop Med Hyg 49: 657-63.

  8. Lairmore MD, Jacobson S, Gracia F, De BK. Isolation of Human T cells linphotropic virus type 2 fron Guaymi Indians in Panamá. Proc Nac Acad Sci USA 1990; 87: 8840-4.

  9. Roman GC, Schomberg BS, Maddeen EL, et al. Human T lynphotropic virus type I antibodies in serum of patients with tropical spastic paraparesis in the Seychelles. Arch Neurol 1987; 44: 605-8.

  10. Cartier L, Gormaz A, Araya F, Castillo Jl. Cognitive functions in progressive spastic paraparesis associated to HTLV-1: a preliminary study. Rev Chil de Neuropsiquiat 1992; 30: 241-6.

  11. Singhal BS, Lalkaka JA, Ladiuala Uma. Tropical spastic paraaparesis in India. In: HTLV, Truths and questions. Zaninovic W (ed.). U. del Valle. Cali.

  12. Alarcón T, Hidalgo C, Aguirre R, et al.: Paraparesia espástica Tropical en el Ecuador. Medicina de Hoy 1990; 9: 48-53.

  13. Roman GC, Osame M. Identity of HTLV-1 associated Tropical spastic Para paresis and HTLV-1 associated myelophaty. Lancet. 1998. 1:651.

  14. Saito M, Furukawa A, Osame M, Yoshida M.: Frequent mutation in px region of HTLV-1 is observed in HAM/TSP patient, but is not specifically associated with CNS lesions. J Neurovirology 1995; 1: 286-94.

  15. Jacobson S, Reuben Js, Palker T. Induction of CDA Humajn T lynphotropic virus type I specific cytotoxic, with patients HAM/TSP. J Inmunol1991; 1465: 1115-62.

  16. Ijichi SN, Osamen M, et al. In vitro modulation of lynphocites proliferation of prednisone in patient of HTLV- 1 associated with HAM. O Neuroinm unology. 1989; 23: 175-8.

  17. Roman GC, Spencer PS, Schomberg BS. Tropical myeloneuropathies: the hidden endemias. Neurology 1985; 35: 1158-70

  18. Osame M. Review of WHO Kagoshima Meeting and diagnostic guidelines from HAM/TSP In: Blattner WA (ed.). Human retrovirology RP1990, p. 191-7.

  19. Johnson RT, McArthur GC. Myelophaties and retroviral infections. Ann Neurol 1988; 21: 113-16.

  20. Roman GC. Tropical spastis paraaparesis and HTLV-1 myelitis. In: Vinken PJ (eds.). Handbook of Clinical Neurology. Vol 12. Amsterdam: Elsevier; 1989.

  21. Alarcón T, Hidalgo C. Aguirre R, et al. Paraparesia espástica tropical en el Ecuador. Rev Ecuatoriana de Neurología: 1(2): 54-60.

  22. Aboulafia DM, Feigal E, Vranzan K. Human T cell leukemia virus (HTLV-1 HTLV-2) serodiagnostic testing: diparate results among a cohort of intravenus users. AIDS Res Hum Retrovirosis 1993; 9: 1043-50.

  23. Aoki T, Miyahosi H, Koide H, et al. Seroepidemiology of HTLV-1 in residents in Nugata Prefecture. Japan, Int. I. Cancer 1985; 35: 301-6.

  24. Gessain A, Claudie C, Gout O, et al. Intrathecal synthesis of antibodies to HTLV-1 in the presence of IgG of oligoglonal bands in the CSF patients with endemis tropical spastic paraparesis. J Inf Dis 1988; 157: 1226-34.

  25. Gessain A, Louie A, Gallo RC. Human T cell leukemialymphoma virus type I (HTLV-1) expression in fresh peripherical blood with TSP/HTLV-1 associated myelophaty. J Virol 1991; 65: 1628-33.

  26. Richardson JH, Edwards AJ, Cruickshank P. In vivo cellular tropism of human T cell leukemia virus type I. J Virol 1990; 64: 5682-7.

  27. Kira T, Itoyama Y, Koyanogy G, et al. Presence of HTLV-1 proviral DNA in central nervous system in patients with HTLV-1 associated myelophaty. Ann Neurol 1992; 31: 39-45.

  28. Grimaldi, et al. HTLV-I associated myelophaty:oligoclonal G bands contain anti HTLV-I p24 antibody. Ann Neurol 1988; 24: 727-31.

  29. Sugimoto M, Nakashiwa T, Wanatabe S, et al. T lymphocytes alveolitis in HTLV-1 associated myelophaty. Lancet 1987; I: 1220.

  30. Ozden G, Coscoy L, Gozalez Dunia D. HTLV-1 tropism and HAM/TSP pathogenesis. In. HTLV-1. Tryhs and questions. Zaninovic (ed.). Fundacion; 1996, p. 39-56.

  31. Dougond F, Buckle G, Hafler D, Hollsberg P. Inmunology of HTLV-1 infection. In: HTLV-1 Thrus and Questions. Zaninovic V (ed.). Fundación; 1986, 78-88.

  32. Jacobson S, Parker T. Induction of CDA Human T lymphotropic virus type I specific citotoxic T lymphocitos from patients with HAM/TSP. J Inmunol 1991.

  33. Parker CE, Doenke S. Activated HTLV-1 especific cytotoxic T lymphocites are found and healthy seropositives as well as in patients with TSP. Virology 1992; 128: 628.

  34. Castro-Costa CM, Dom R, Cartom H, Goubaun P, et al. A pathologycal analysis of two first s Brazilians autopsies cases oh HAM/TSP. J Adquir Defc Synd Human Retrovirol 1995; 10: 229.

  35. Leon F, Alarcón T. HAM/TSP in Ecuador. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1995; 89; 342. Corresopondence.

  36. Alarcón T, Aguirre R, Diaz E, y colbs. TSP en el Ecuador. Actas VIII Congreso Panamericano de Neurología. Actas 6- 12. Montevideo- Uruguay. 1991.

  37. Román G, Mora C, Alarcón T. HTLV-1 associated TSP in South America new cases in Ecuador, Brazil and Paraguay. Annual Meeting 1991; 1-8.

  38. Ludolph AC, Hugon J, Roman GC, et al. A clinical neurophysiological study of TSP. Muscle And Nerve 1988; 11: 392-7.

  39. Sheremata WA Quencer R, Gatti E, et al. MRI of tropical spastis paraparesis. Neurology 1987(Suppl.)1: 332. Abstract.

  40. Howard AK, Oger J. MRI contributes to the diderntiaton between Ms and ATLV-I asisociated myelophaty in British Columbian coastal natives. Can J Neurol Sci 2003; 30: 41-8.

  41. Johnson RT, Griffind D, Arregui A, et al. Spastic paraparesis and HTLV-1 infection in Peru. Ann Neurol 1988; 23(Suppl.): S151-S155.

  42. Arango C. Phylogenetics of HTLV-1. In: HTLV. Truth and Questions. Zaninovic V (ed.). Fundación del Mar; 1996.

  43. Usuku K, Sonoda S, Osamen M, et al. HLA haplotype-linked higu immune responsivennes against HTLV-1 in HTLV-1 associated myelophaty: comparison with adult T-cell leukemia-lymphoma. Ann Neurol 1988; 23(Suppl.) 143-50.

  44. Román GS. The neuroepidemiology of TSP. Ann Neurol 1988 (Suppl.): S113-S120.

  45. Petito CK. Review of central nervous system pathology in human immunodeficiency virus infection. Ann Neurol 1988(Suppl.): S54-S57.

  46. Alarcón AT, Alarcón GT, Román GS. Infección Neurológica por HTLV-1. Rev Ecuat Neurol 2001: 10: 76-80.

  47. Tournier-IasserveE, Gout O, Gessain A, et al. HTLV-1 brain anormalities on magnetei resonance imaging in relation with multiple scleroris. Lancet 1987; 2: 49-50.

  48. Cruickshand EK. A neurophetic syndrome of uncertain origin. West Indian Medical J 1956: 5: 147-58.

  49. Román GS. TSP and HTLV-I myelitis. Handbook of Clinical Neurology. Vol. 12-56. Viral Disease. Elsevier Sc. Publishers; 1989.

  50. Wong-Staal F, Gallo RC. Human lymphotropic retroviruses. Nature 1985; 317: 395-403.

  51. Sheremata WA, Squilicote DC, De Freitas E. A safety study of high doses retrovir (AZT) in HTLV-1 associated myelophaty (HAM). Evidence fpr safety and possible efficacy. Neurology 1991.

  52. Alarcón T, Alarcón AT. Tratamiento de la Paraparesia espástica tropical con Pentoxifilina: Estudio Piloto. Rev Ecuat Neurol 2002: 11: 40-3.

  53. Izumu S, Uzuki K, Osame F. Effect of Alpha Interpheron treatment of HTLV-1 associated myelophaty . Neurology 1998; 38(Suppl.): 242.

  54. Monikawa K, Oseko F, et al. Immunomodulatory effect of fosfomicine of human B lymphotrophic function. Antimicrob Agents Chem 1993; 37: 270-5.

  55. Ward A, Clissold SP. A review of its pharmacodinamic and pharmacokinetic properties, and its therapeutics efficacy. Drugs 1987; 34-50.

  56. Matsuo K and et. Plasmapheresis in treatment of HTLV-1 associated myelophaty. Lancet 1988: 2: 1109-13.

  57. Nakawaga M, Nakaahara K, Maruyama Y, Thjerapeutric trial in 200 patients with HTLV-1 associated myelophaty/ TSP. J. Neurovir ( in press).

  58. Calero G, Ollague J, et al.: Patología cutánea relacionada a infección por virus HTLV-1. Dermatoloía. Vol 7.No 1. 1998. Pag 4-9.

  59. Zanonovic V (ed). Truths and Questions. Cali-Colombia: Fundación del Mar; 1996.

  60. Rovetto D. What do I have learned from HTLV-1? In: Zaninovic V (ed.). HTLV. Truths and Questions. Cali- Colombia: Fundación Mar; 1996.

  61. Puccione Sohler M, Yamano Y, et al. Differentiation of HAM/TSP from patients with multiple sclerosis infected with HTLV-I. Neurology 2007; 68(3): 206-13.

  62. Poiesz BJ, Ruscetti F, GHasdar T, et al. Detection and isolation of type C Retrovirus particles from fresh and cultuyred in patient with HTLV-1. Proc Natal 1980.

  63. Eloovara I, Koening S, Brewak R. High human T lymphotropic vrus type HTLV-1 especific precursos cytotoxic T lynphocites frecuency in patients with HTLV- 1 associated neuroilogycal disease. J Expect Med 1993; 177: 1567-63.

  64. Kira T, Koyanagy G, et al. Presence of HTLV-1. Proviral DNA. Ann Neurol 1992; 31: 39-45.

  65. Carvalho SMF, Pombo de Oliveira, et al. HTLV-I and HTLVII infection and hematologic disorder partients, cancer patients and healthy individuals from Rio de Janeiro, Brazil. J AIDS 1997; 15: 238-42.




2020     |     www.medigraphic.com